Alkermes rises as analyst says Elan deal will make company profitable; pipeline 'interesting'
On Tuesday August 30, 2011, 1:33 pm EDT
NEW YORK (AP) -- Shares of drug developer Alkermes Inc. edged higher Tuesday after a Caris & Co. analyst upgraded the stock, pointing to the company's pending acquisition of a drug technology business.
THE SPARK: Analyst Mario Corso upgraded shares of the Waltham, Mass., company to "buy" from "average," saying the share price drop doesn't reflect the company's value. He said the purchase of Elan Corp. PLC's drug delivery business, which is scheduled to close by the end of September, will make Alkermes profitable.
Corso said that over the next few years, revenue from newer products like the multiple sclerosis treatment Ampyra and antipsychotic drug Invega Sustenna and from its diabetes drug candidate Bydureon will cancel out a drop in sales of older products like Risperdal Consta.
The analyst added that Alkermes has an "interesting" drug pipeline that includes potential treatments for opioid-induced constipation, depression, and schizophrenia.
Alkermes sells the addiction treatment Vivitrol. Most of the other products it helped develop, like Ampyra and Invega Sustenna, are marketed by other companies. It also manufactures Risperdal Consta for Johnson & Johnson.
THE BIG PICTURE: Alkermes agreed to buy Elan Drug Technologies in May for $960 million in cash and stock. It will reincorporate in Ireland after the deal closes. Alkermes, along with its partners Eli Lilly & Co. and Amylin Pharmaceuticals Inc., is waiting for the Food and Drug Administration to make a decision on their long-lasting diabetes treatment Bydureon. They expect the FDA to make decision on the drug in late January.
Corso is the second analyst to upgrade the stock in the last week. On Aug. 23, UBS analyst Ami Fadia upgraded the shares to "buy" from "neutral," citing similar reasons.
SHARE ACTION: Shares of Alkermes gained 65 cents, or 4 percent, to $16.98 in midday trading.
Alkermes shares set a 52-week high of $20 July 8, but had lost almost 25 percent of their value by the time of Fadia's upgrade. The stock is up 5 percent since then. Corso raised his price target to $22 per share from $19.
In the past year, the shares have traded as low as $9.85.
Recent ALKS News
- Alkermes to Report Second Quarter Financial Results on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:00:00 PM
- Alkermes to Report Second Quarter Financial Results on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:56:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:55:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:01:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:53:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:51:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:49:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:45:15 PM
- Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 • PR Newswire (US) • 06/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:10 PM
- Alkermes to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 05/29/2024 08:00:00 PM
- Alkermes to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 05/29/2024 08:00:00 PM
- Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 • PR Newswire (US) • 05/28/2024 11:00:00 AM
- Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 • PR Newswire (US) • 05/28/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/14/2024 08:30:08 PM
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences • PR Newswire (US) • 05/14/2024 11:00:00 AM
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences • PR Newswire (US) • 05/14/2024 11:00:00 AM
- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk • PR Newswire (US) • 05/02/2024 11:00:00 AM
- Alkermes plc Reports First Quarter 2024 Financial Results • PR Newswire (US) • 05/01/2024 11:00:00 AM
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 • PR Newswire (US) • 04/24/2024 11:00:00 AM
- Alkermes to Report First Quarter Financial Results on May 1, 2024 • PR Newswire (US) • 04/17/2024 08:00:00 PM
- Alkermes to Report First Quarter Financial Results on May 1, 2024 • PR Newswire (US) • 04/17/2024 08:00:00 PM
- Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia • PR Newswire (US) • 04/09/2024 11:00:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM